InSyBio has joined the Loyal VC program which includes an initial investment from the Toronto, Canada based international fund and provides InSyBio with access to Loyal VC’s global network of over 400 advisors and experienced entrepreneurs, accelerator leaders, advisors, angels and venture investors.
InSyBio will benefit from active business development support and guidance as well as having access to various valuable resources and services as part of the Loyal VC program.
InSyBio’s CEO Labros Digonis stated: “with the Loyal VC program we shall speed up the completion of our open ﬁnancing round and accelerate the accomplishment of both our business and technological targets, most important of which are:
- The launching and commercialization of the InSyBio Precision Chronic Pain Treatment Tool
- To continue improving the InSyBio Suite by incorporating our clients’ feedback and by integrating additional tools in it like Thematic platforms for Cancer, Neurodegenerative Diseases and Nutrition
- And eventually to evolve at such a level where the InSyBio suite will be the platform of choice for the discovery of biomarkers from single and multi-omics data.” And ﬁnally he added “between Insybio and Loyal VC it surely begins an encouraging win-win situation”
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical ﬁeld, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
About Loyal VC: Loyal VC operates a global startup index fund with over 160 investments across more than 38 countries. The fund is designed to minimize systemic bias inherent in the investment process, unlocking greater returns. The Loyal Startup Index Fund has delivered strong returns since its launch in 2018, thanks to its collaborative, staged investment process, its network of over 400 advisors, and its global relationships with the Founder Institute, the world’s largest pre-seed accelerator, and INSEAD, rated the #1 non-US business school for unicorn founders by Pitchbook. Loyal’s global start-up index fund is inclusive of a diverse, often mission-driven, group of entrepreneurs. To date over 30% of the portfolio have a woman CEO, almost 30% are from emerging markets, and around 80% address one or more of the United Nation’s Sustainable Development Goals (UNSDGs).
For more information visit www.loyal.vc.
For more News visit our InSyBio Blog.